SCHEMBL5380294

SCHEMBL5380294

Cc1cc(N2C[C@@H]3[C@H](C2)[C@H]3NC(=O)OC(C)(C)C)n2nc(-c3ccccc3Cl)c(-c3ccc(Cl)cc3)c2n1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.43
HPGD P15428 3/20 0.42
HSD17B10 Q99714 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CNR1 P21554 2/20 0.42
CNR2 P34972 2/20 0.42
MAPT P10636 4/20 0.42
POLB P06746 3/20 0.42
TP53 P04637 3/20 0.41
RXFP1 Q9HBX9 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.39
ALDH1A1 P00352 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
KDM4E B2RXH2 1/20 0.38
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
CRHR1 P34998 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5380182 0.83 HPGD (0.54) THRBHPGDHSD17B10SMN1; SMN2CNR1
SCHEMBL5380598 0.82 KMT2A (0.48) THRBHPGDHSD17B10SMN1; SMN2MAPT
SCHEMBL5381302 0.79 THRB (0.39) THRBHPGDHSD17B10SMN1; SMN2CNR1
SCHEMBL5377478 0.77 HSD17B10 (0.59) THRBHPGDHSD17B10SMN1; SMN2MAPT
SCHEMBL5391857 0.75 KMT2A (0.56) HPGDHSD17B10SMN1; SMN2MAPTPOLB
SCHEMBL5384083 0.75 KMT2A (0.55) HPGDHSD17B10SMN1; SMN2CNR1CNR2
SCHEMBL14577551 0.74 KMT2A (0.51) THRBHPGDHSD17B10SMN1; SMN2MAPT
SCHEMBL5386475 0.74 KMT2A (0.51) THRBHPGDHSD17B10SMN1; SMN2MAPT
SCHEMBL5390202 0.74 CNR1 (0.53) THRBHPGDHSD17B10SMN1; SMN2CNR1
SCHEMBL5376034 0.74 KMT2A (0.52) HPGDHSD17B10SMN1; SMN2CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
EP-1594872-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF Pfizer Products Inc. (US) 2005-11-16 EP disclosed
WO-2004069838-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2004-08-19 WO disclosed
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 THRB 383/4885HPGD 1567/4885HSD17B10 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.